Relay Therapeutics Shares Gain After Oppenheimer Upgrade; Analyst Sees Competitive Opening
Relay Therapeutics Inc (NASDAQ: RLAY) saw premarket gains after Oppenheimer upgraded the stock from Perform to Outperform and set a $14.00 price target. Analyst Matt Biegler pointed to a possible competitive tailwind for Relay's mutant-selective PI3K inhibitor zovegalisib if gedatolisib's upcoming VIKTORIA-1 readout disappoints in PI3K-mutant patie…